With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access

Merck is making significant strides in ensuring access to a new H.I.V. prevention pill, with companies in Africa and India set to produce generic versions at an affordable price of $5 per person per year. This move aims to address the critical need for accessible healthcare solutions, especially in regions like Africa where H.I.V. remains a significant public health challenge. However, the availability in Latin America remains uncertain, highlighting the ongoing disparities in healthcare access across different parts of the world. This development underscores the importance of global pharmaceutical strategies in combating widespread health crises.